AML Blood Test – A new method for the early detection and prognosis of acute myeloid leukemia
Diagnosing acute myeloid leukemia (AML) is difficult due to the lack of specificity of symptoms. Thus, AML is often mistakenly diagnosed as an infection or a general fatigue.
Tragically, AML progresses extraordinarily fast. Thus, any delay in diagnosis/treatment results in a loss of precious time for life-saving chemotherapy. Scientists from the University of Bonn developed an innovative RNA-fingerprint-based test of peripheral blood samples. Data sets from more than 4.000 patients demonstrate a specificity of > 0,996 and a sensitivity of > 0,992. By using peripheral blood samples, the test is easily applicable. With the diagnosis also being fast and cost-efficient, the present invention is also applicable (as an exclusion diagnosis) by the general practitioner.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…
